Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.
McNally
O M
OM
Department of Gynaecology/Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland. omcnally@doctors.org.uk
Delaney
E
E
Petty
R D
RD
Cruickshank
M E
ME
Hutcheon
A W
AW
Parkin
D E
DE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000175:diagnosis / Q000188:drug therapy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017410:Practice Guidelines as Topic / Q000592:standards; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D015996:Survival Rate; D043823:Taxoids
D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; D017239:Paclitaxel